The company operates as an antibody discovery and development platform, generating revenue through partnerships with pharmaceutical companies, biotechnology firms, and government or non-profit organizations. It offers proprietary antibody discovery and development services that enable partners to identify high-quality antibodies for therapeutic applications, with the vast majority of economic value derived from downstream milestone payments and royalties on drug sales rather than upfront fees. The company also maintains an internal pipeline of drug candidates developed using its platform, though it remains pre-commercial without any marketed proprietary drugs and relies on partners' success in clinical development, regulatory approval, and commercialization to realize financial returns from its discoveries.